EMEA-001143-PIP01-11-M04

Table of contents

Key facts

Invented name
  • Cometriq
  • Cabometyx
Active substance
cabozantinib
Therapeutic area
Oncology
Decision number
P/0357/2022
PIP number
EMEA-001143-PIP01-11-M04
Pharmaceutical form(s)
  • Age-appropriate oral solid dosage form
  • Tablet
  • Capsule, hard
Condition(s) / indication(s)
Treatment of solid malignant tumours
Route(s) of administration
Oral use
Contact for public enquiries
Ipsen Pharma

E-mail: GlobalMedInfo@ipsen.com
Tel.: +33 158335427

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating